Alumis Inc. reports clinical, financing and corporate updates as a late-stage biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases. Its pipeline centers on oral TYK2 inhibitors, including envudeucitinib for systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for neuroinflammatory and neurodegenerative diseases. The company also lists lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, and preclinical programs identified through its precision approach.
Recurring ALMS news includes envudeucitinib clinical data from the ONWARD and STRIDE programs, disease-biomarker presentations, financial results, investor conference communications and common-stock financing activity.
Alumis (Nasdaq: ALMS) closed an upsized underwritten public offering on January 9, 2026, selling 20,297,500 shares of common stock at $17.00 per share, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares. The gross proceeds to Alumis were approximately $345.1 million before underwriting discounts, commissions and offering expenses. All offered shares were sold by Alumis under a shelf registration on Form S-3 declared effective on August 19, 2025. Joint book-running managers and co-lead managers were named for the transaction. The company noted prospectus documents are available on the SEC website and from the listed managers.
Alumis (Nasdaq: ALMS) priced an upsized underwritten public offering of 17,650,000 shares at $17.00 per share, generating approximately $300.0 million in gross proceeds before fees. The company is selling all shares and granted the underwriters a 30-day option to buy up to an additional 2,647,500 shares at the public offering price, less discounts and commissions. The offering is expected to close on January 9, 2026, subject to customary closing conditions. The offering is being conducted under an SEC-declared effective shelf registration and will be documented in a final prospectus filed with the SEC.
Alumis (Nasdaq: ALMS) announced on January 6, 2026 its plan to commence an underwritten public offering of $175.0 million of common stock, with Alumis as the seller.
The company also expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares. The offering is subject to market and other conditions and may not be completed.
Joint book-running managers for the proposed offering are Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities. A preliminary prospectus supplement will be filed with the SEC and be available on sec.gov.
Alumis (Nasdaq: ALMS) reported positive topline Phase 3 results for oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis from ONWARD1 and ONWARD2.
Key highlights: across both trials PASI 75 74%, sPGA 0/1 59% at Week 16; at Week 24 ~65% PASI 90 and >40% PASI 100. Rapid separation from placebo on PASI 90 by Week 4. Envudeucitinib was superior to placebo and apremilast (p<0.0001) on primary endpoints. Safety through Week 24 was consistent with Phase 2; common TEAEs included headaches, nasopharyngitis, upper respiratory infections, and acne. Alumis plans an NDA submission in H2 2026 and will present additional data at a future medical meeting.
Alumis (Nasdaq: ALMS) will report topline results from the Phase 3 ONWARD program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 2026.
The company will host a conference call and webcast to discuss the topline data at 8:00 a.m. ET. Investors may access the live webcast via the company’s Investors > Events page at www.alumis.com. A replay of the webcast will be available on the company website after the call.
Alumis (Nasdaq: ALMS) reported third quarter 2025 results and program milestones on Nov 13, 2025. Cash, cash equivalents and marketable securities were $377.7 million as of Sept 30, 2025, which the company expects will fund operations into 2027. Revenue for the quarter included $2.1 million of collaboration revenue. R&D expense was $97.8 million and G&A was $19.5 million for Q3 2025; net loss was $110.8 million. Key clinical milestones: topline Phase 3 ONWARD envudeucitinib (PsO) data expected early Q1 2026 and Phase 2b LUMUS (SLE) topline in Q3 2026; A-005 Phase 2 MS start planned H1 2026.
Alumis (Nasdaq: ALMS) will participate in two investor conferences in November 2025: Guggenheim Healthcare Innovation Conference in Boston (Nov 10-12) with a fireside chat on Nov 11, 2025 at 1:30 PM ET, and the Stifel 2025 Healthcare Conference in New York (Nov 11-13) with a presentation on Nov 12, 2025 at 2:00 PM ET.
Live webcasts will be available via the company’s Investors > Events page, and replay archives will remain on the website for 90 days.
Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated disease therapies, has announced its participation in six major investor conferences during September 2025. The company will present at the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum.
All presentations will be accessible via webcast through Alumis's investor relations website, with replays available for 90 days following each event.
Alumis (Nasdaq: ALMS) reported Q2 2025 financial results and significant clinical progress. The company completed enrollment in two major trials: the Phase 3 ONWARD trials for envudeucitinib in plaque psoriasis (topline data expected Q1 2026) and the Phase 2b LUMUS trial for systemic lupus erythematosus (topline data expected Q3 2026).
Key financial highlights include $486.3 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $2.7 million from the Kaken Pharmaceutical collaboration. The company reported a net income of $59.3 million, including a $187.9 million gain from the ACELYRIN merger.
R&D expenses increased to $108.8 million (vs $48.6M in Q2 2024), while G&A expenses rose to $34.5 million (vs $7.6M in Q2 2024). The merger with ACELYRIN added $382.6 million to the company's cash position.
Alumis (Nasdaq: ALMS) has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE). The trial has enrolled 408 patients who will receive ESK-001 or placebo for 48 weeks.
The study will evaluate the drug's efficacy in treating moderately-to-severely active, autoantibody-positive SLE, with topline data expected in Q3 2026. The primary endpoint will measure disease activity improvements using the BICLA assessment at Week 48. The company reports that ESK-001 has shown promising results in their psoriasis program, demonstrating full target inhibition and general tolerability.